Korea’s Hanmi Hopes U.S. Esomeprazole Launch Will Counter Disappointing China Results
This article was originally published in PharmAsia News
Executive Summary
As Hanmi gears up for a U.S. launch of its modified version of AstraZeneca’s Nexium, it is also expanding global R&D initiatives to differentiate itself.
You may also be interested in...
Crestor Patent Settlement Allows Actavis Generic Entry In May 2016
The agreement permits Actavis to launch its generic version of AstraZeneca’s Crestor 67 days before the patent on the cholesterol-lowering drug expires in return for paying AstraZeneca 39% of its net sales during this period; Actavis may also launch its alternative zinc salt formulation of Crestor at the same time.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.